Evidence map›Paper›PMID 33326576›Full record

ArticleThe Journal of infectious diseases2021

Risk Factors for Non-Human Papillomavirus (HPV) Type 16/18 Cervical Infections and Associated Lesions Among HPV DNA-Negative Women Vaccinated Against HPV-16/18 in the Costa Rica Vaccine Trial.

Mónica S Sierra, Sabrina H Tsang, Shangying Hu, Carolina Porras, Rolando Herrero, Aimée R Kreimer, John Schussler, Joseph Boland, Sarah Wagner, Bernal Cortes and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 4 countries.

Mónica S SierraDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0003-1286-057X
Sabrina H TsangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Shangying HuDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Carolina PorrasAgencia Costarricense de Investigaciones Biomédicas, formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica.
Rolando HerreroAgencia Costarricense de Investigaciones Biomédicas, formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica.
Aimée R KreimerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
John SchusslerInformation Management Services, Silver Spring, Maryland, USA.
Joseph BolandDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Sarah WagnerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0002-0223-2388
Bernal CortesAgencia Costarricense de Investigaciones Biomédicas, formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica.
Ana C RodríguezIndependent Consultant, San José, Costa Rica.
Wim QuintDDL Diagnostic Laboratory, Rijswijk, The Netherlands.
Leen-Jan van DoornDDL Diagnostic Laboratory, Rijswijk, The Netherlands.
Mark SchiffmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Joshua N SampsonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Allan HildesheimDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0003-0257-2363
Costa Rica Human Papillomavirus Vaccine Trial (CVT) Group
National Cancer Institute · USInstituto Costarricense de Investigación y Enseñanza en Nutrición y Salud · CRDDL Diagnostic Laboratory · NLLeidos (United States) · USInformation Management Services · US

Funding

HPV Vaccine TrialZIACP010217 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI KREIMER, AIMEE · 2011 to 2025
$42.3M
NCI NIH HHS N01 CP011005World Health Organization 001
6 · The paper itself

Abstract

backgroundFactors that lead human papillomavirus (HPV) infections to persist and progress to cancer are not fully understood. We evaluated co-factors for acquisition, persistence, and progression of non-HPV-16/18 infections among HPV-vaccinated women.

methodsWe analyzed 2153 women aged 18-25 years randomized to the HPV-vaccine arm of the Costa Rica HPV Vaccine Trial. Women were HPV DNA negative for all types at baseline and followed for approximately 11 years. Generalized estimating equation methods were used to account for correlated observations. Time-dependent factors evaluated were age, sexual behavior, marital status, hormonally related factors, number of full-term pregnancies (FTPs), smoking behavior, and baseline body mass index.

resultsA total of 1777 incident oncogenic non-HPV-16/18 infections were detected in 12 292 visits (average, 0.14 infections/visit). Age and sexual behavior-related variables were associated with oncogenic non-HPV-16/18 acquisition. Twenty-six percent of incident infections persisted for ≥1 year. None of the factors evaluated were statistically associated with persistence of oncogenic non-HPV-16/18 infections. Risk of progression to Cervical Intraepithelial Neoplasia grade 2 or worst (CIN2+) increased with increasing age (P for trend = .001), injectable contraceptive use (relative risk, 2.61 [95% confidence interval, 1.19-5.73] ever vs never), and increasing FTPs (P for trend = .034).

conclusionsIn a cohort of HPV-16/18-vaccinated women, age and sexual behavior variables are associated with acquisition of oncogenic non-HPV-16/18 infections; no notable factors are associated with persistence of acquired infections; and age, parity, and hormonally related exposures are associated with progression to CIN2+.

Indexed as

Papillomavirus InfectionsPapillomavirus VaccinesAdolescentAdultCosta RicaDNAFemaleHuman papillomavirus 16Human papillomavirus 18HumansPapillomaviridaePregnancyRisk FactorsTreatment OutcomeUterine Cervical DysplasiaUterine Cervical NeoplasmsDNAPapillomavirus VaccinesCIN2+HPV infectionHPV vaccineincidencepersistenceprogression

Identifiers

PMID33326576
PMCPMC8496490
OpenAlexW3115161555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.